<DOC>
	<DOC>NCT00853112</DOC>
	<brief_summary>Study will assess PF-00489791 efficacy and safety in Pulmonary Arterial Hypertension (PAH)</brief_summary>
	<brief_title>A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Pfizer decided to stop this trial early upon Stage 1 completion due to change in PF-00489791 development and not as a result of safety concerns for PF-00489791. Date of termination (LSLV) occurred on July 28, 2010.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Idiopathic or familial pulmonary arterial hypertension (PAH) Mean PAP at least 25 mm Hg, PCWP &lt; 15 mm Hg at rest For females of childbearing potential negative pregnancy test at screening and use of contraception during the study and 4 weeks after its completion Signed and dated informed consent Willingness to comply with the study plan and procedures pulmonary arterial hypertension (PAH)other than idiopathic or familial For females, pregnancy or lactation Use of specific PAH treatments, potent CYP3A4 inhibitors, protease inhibitors, alpha blockers or arginine 30 days prior tio randomization and during the study Change of dose or class of standard background PAH therapy, i.e. oxygen, calcium channel blockers, digoxin, diuretics 30 days prior tio randomization and during the study Large shift in altitude (defined as &gt;5000 feet or 1524 meters) during 90 days prior to baseline visit and/or during the study visit Subjects with intracardiac shunts and/or serious heart, lung or other health conditions HIV positive subjects Subjects participating in another clinical trial with an investigational drug or device Subjects with degenerative retinal disorders, history of nonarteritic anterior ischemic optic neuropathy or untreated proliferative diabetic retinopathy Allergies and previous intolerance of PDE5 inhibitors Alcohol or drug abuse Blood donation during the study, or 1 month before or after the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>PAH pulmonary hypertension pulmonary arterial hypertension</keyword>
</DOC>